June 16, 2008
Maximus Features MaxPlus Clear(R) and New Clinical Research at Association for Professionals in Infection Control and Epidemiology Annual Conference June 15-17
Maximus, a business unit of leading infusion therapy firm Medegen Inc., will exhibit at the Association for Professionals in Infection Control and Epidemiology (APIC) annual scientific conference, June 15-17 in Denver, Colorado. The exhibit will feature the new MaxPlus(R) Clear, the first and only clear positive displacement connector for use in patient care, as well as two award-winning clinical research posters.
The first, an abstract authored by Victor Lange, ICP, CRC entitled "Needleless Valves/Connectors: Infection Prevention" is the first place winner of the Clinical Innovations/Practice Abstract Presentation awarded by the Infusion Nursing Society Conference held May 3-8, 2008 in Phoenix, Ariz. In this study, the latest FDA requirements for microbial ingress testing of a needleless access device were performed on three different devices. Results confirmed that the MaxPlus connector with Tru-Swab(TM) technology is clinically superior to the two additional products tested in terms of microbial barrier properties when using common disinfection protocol and worst case clinical simulation.
Maximus is the only needleless access device manufacturer to test their needleless access device against these new, more rigorous FDA standards and publish the results. In 2007, Maximus received 510K clearance for the claim of "meets and exceeds latest FDA guidance for microbial ingress testing."
Maximus will also display the first place winner of the 2008 Infusion Nurses Society Scientific Poster Contest for Clinical Research, authored by Andre' Schotte, RN, PhD, entitled "Luer Activated Device (LAD) Performance". In this study, clinical data was collected to compare the MaxPlus positive displacement connector to an alternative "neutral" connector for number of catheter occlusions over a seven week period. During this period, the MaxPlus connector experienced only one withdrawal occlusion and no total occlusions, whereas the alternate device experienced 11 withdrawal occlusions and nine total occlusions. To determine why there was such a discrepancy, the author conducted independent laboratory testing and discovered that out of nine different connectors tested, only the MaxPlus connector exhibited positive displacement which reduces the occurrence of blood reflux into the catheter at disconnect. The eight other connectors all exhibited negative reflux, including the connectors that claim to be neutral. Negative displacement connectors permit reflux of blood into the catheter when the syringe or administration set is removed from the connector. As evidenced in the clinical research, this can lead to occlusions.
"The results of these two meaningful research efforts illustrate the clinical impact of the MaxPlus device," said Jeff Goble, President of Medegen. "The annual meeting is a great way for nurses and infection control practitioners to see how the MaxPlus Clear Connector promotes best practice by allowing for thorough disinfection and flushing."
MaxPlus Clear is the first and only clear positive displacement connector shown to enhance patient care by lowering bloodstream infection and occlusion rates.
For more information on the conference, visit http://conference.apic.org//AM/Template.cfm?Section=Home3
About Medegen Inc.
Medegen is a leading innovator in infusion therapy, focused on helping hospitals drive greater clinical performance for improved patient care. The growing company provides clinically superior medical products and reliable, cost-effective manufacturing services to the medical community through its three operating units: Manufacturing Services, Maximus and KippMed. Manufacturing Services provides cost-effective contract manufacturing solutions to medical device, drug delivery and pharmaceutical companies. KippMed manufactures and markets IV therapy components for the OEM market, drawing from a 25-year history in IV component supply. Maximus develops, manufactures and markets needleless intravenous therapy products for the acute care market. The Maximus line of medical products features patent-protected technologies which improve patient outcomes and greatly reduce bloodstream infection rates. Medegen is headquartered in Ontario, Calif. with executive offices in Scottsdale, Ariz. and operations in Tijuana, Mexico. For more visit http://www.medegen.com/.